Skip to main content
IDWeek 2023 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
Live Streamed
On Demand
On Demand
Back

150. HIV: Treatment: Friday, 12:15 - 1:30 p.m.

Poster Session: HIV: Treatment

(1603) Efficacy, safety and tolerability of switching to dolutegravir/lamivudine in virologically suppressed adults living with HIV on bictegravir/emtricitabine/tenofovir alafenamide -the DYAD study

Friday, October 13, 2023
12:15 PM – 1:30 PM US ET
Location: Hall B + C

    Presenting Author(s)

  • CR

    Charlotte-Paige M. Rolle, MD, MPH (she/her/hers)

    Director of Research Operations
    Orlando Immunology Center, Orlando, FL, USA
    Orlando, Florida, United States

    • Co-Author(s)

  • JC

    Jamie Castano, MA

    Orlando Immunology Center
    Orlando, Florida, United States

  • VN

    Vu Nguyen, MS

    Statistician
    Orlando Immunology Center
    Orlando, Florida, United States

  • FH

    Federico Hinestrosa, MD

    Associate Medical Director
    Orlando Immunology Center, University of Central Florida College of Medicine
    Orlando, FL, United States

  • ED

    Edwin DeJesus, MD

    Medical Director
    Orlando Immunology Center, University of Central Florida College of Medicine
    Orlando, FL, United States